Symbols

UPB

Upstream Bio·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About UPB

Upstream Bio, Inc.

A clinical biotechnology company focused on developing treatment methods for inflammatory diseases, with a particular emphasis on severe respiratory diseases

Industry

Biological Technology

Established Date

Listing Date

10/11/2024

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.upstreambio.com

Security Type

Common stock

Office address

890 Winter Street, Suite 200, Waltham, MA 02451

Business

Introduction

Upstream Bio, Inc., was incorporated in Delaware in April 2021. They are a clinical-stage biotechnology company developing treatments for inflammatory diseases, initially focusing on severe respiratory diseases. They are developing verekitug, the only known antagonist currently in clinical development, targeting the thymic interstitial lymphopoietin (" TSLP ") receptor, a cytokine that is a clinically validated driver of inflammatory response located upstream of multiple signaling cascades affecting various immune-mediated diseases. Preclinical and clinical data to date show that verekitug has a highly potent inhibitory effect on TSLP receptors, which will translate into differentiated product features, including the potential to improve clinical outcomes, significantly extend dosing intervals and treat a wide range of patients. Their experienced team is committed to maximizing the unique attributes of verekitug to meet the large unmet needs of patients who are not met by today's standard of care.

Company Financials

EPS

UPB has released its 2025 Q3 earnings. EPS was reported at -0.63, versus the expected -0.78, beating expectations. The chart below visualizes how UPB has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

UPB has released its 2025 Q3 earnings report, with revenue of 683.00K, reflecting a YoY change of 12.52%, and net profit of -33.75M, showing a YoY change of -111.03%. The Sankey diagram below clearly presents UPB's revenue sources and cost distribution.